Search Results

benefiting from further improved outcomes using directed Precision Medicine to alleviate significant medical Alzheimer’s disease with an oral once daily potential solution with the aim to alleviate significant medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Saunders specializes in representing emerging pharmaceutical, medical technology and biotechnology concerns practice, facilitated by his graduate studies in physiology at Case Western Reserve University and Albany Medical Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866

biomarker-driven ANAVEX®2-73 rare disease program into additional late-stage studies with high unmet medical using gene biomarkers of response, applying precision medicine for neurological disorders with unmet medical need: Planned initiation of a pivotal Phase 2/3 study in Fragile X Syndrome, the most frequent genetic Conference Call / Webcast Information The live webcast of the conference call can be accessed online at https projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Kaufmann joined Anavex as Chief Medical Officer. Safety and Tolerability: ANAVEX®2-73 was found to be well tolerated with very good medication compliance About Rettsyndrome.org Rettsyndrome.org is the most comprehensive nonprofit organization dedicated to Rettsyndrome.org, a 501(c)(3) organization, has earned Charity Navigator’s most prestigious 4 star rating Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Clint Tomlinson Email: ir@anavex.com Media

Conference Call / Webcast Information Anavex will host a conference call at 4:30 p.m. The live webcast of the conference call can be accessed online at http://www.wsw.com/webcast/cc/avxl5 (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

Management of symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

– Anavex announced that it had received approval from the Spanish Agency for Medicinal Products and Medical Conference Call / Webcast Information Anavex will host a conference call at 4:30 p.m. The live webcast of the conference call can be accessed online at http://www.wsw.com/webcast/cc/avxl6 (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most

A live webcast of the presentation will be available on http://wsw.com/webcast/cowen46/avxl/. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Clayton

Webcast Information: A live webcast of the presentation will be available via http://wsw.com/webcast/ (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

The fireside chat will be webcast live and can be accessed through the following link https://wsw.com (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Email

Webcast Information: A live webcast of the presentation will be available on http://wsw.com/webcast/cowen52 (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

a competitive molecule into future studies, with the goal of addressing the present and persistent medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most